8,817 results match your criteria Portal Vein Thrombosis

Splanchnic venous thrombosis: aetiologies and a review of the literature.

ANZ J Surg 2022 Jun 25. Epub 2022 Jun 25.

Department of Vascular Surgery, Hollywood Hospital, Perth, Western Australia, Australia.

Background: Splanchnic vein thrombosis (SVT) is an uncommon yet potentially life-threatening manifestation of venous thromboembolism. The aim of this study was to present a retrospective analysis of a cohort of Western Australian patients diagnosed with SVT on imaging study, and a review of the literature surrounding the aetiology, location, anticoagulation treatment and outcomes of SVT.

Methods: All patients diagnosed with SVT over a five-year period from 2015 to 2020 in three tertiary hospitals in Western Australia were identified by using an electronic search engine of imaging reports. Read More

View Article and Full-Text PDF

The portal vein in patients with cirrhosis is not an excessively inflammatory or hypercoagulable vascular bed, a prospective cohort study.

J Thromb Haemost 2022 Jun 23. Epub 2022 Jun 23.

Surgical Research Laboratory and Section of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

Background: A hypercoagulable state is not associated with development of portal vein thrombosis in cirrhosis, as we previously demonstrated. However, some groups demonstrated elevated levels of inflammatory markers and activation of haemostasis in the portal vein (PV) compared to post-hepatic veins, but as the liver is involved in clearance of these markers we hypothesize that interpretation of these data is not straightforward.

Aim: To determine whether the PV has particular proinflammatory/hypercoagulable characteristics by comparing plasma sampled in the PV, hepatic vein (HV) and the systemic circulation. Read More

View Article and Full-Text PDF

Therapy Effect of the Stable Gastric Pentadecapeptide BPC 157 on Acute Pancreatitis as Vascular Failure-Induced Severe Peripheral and Central Syndrome in Rats.

Biomedicines 2022 Jun 1;10(6). Epub 2022 Jun 1.

Department of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.

We revealed the therapy effect of the stable gastric pentadecapeptide BPC 157 (10 μg/kg, 10 ng/kg ig or po) with specific activation of the collateral rescuing pathways, the azygos vein, on bile duct ligation in particular, and acute pancreatitis as local disturbances (i.e., improved gross and microscopy presentation, decreased amylase level). Read More

View Article and Full-Text PDF

A rare complication of umbilical vein catheterization: TPNoma: US, X-ray, and MRI findings.

Curr Med Imaging 2022 Jun 20. Epub 2022 Jun 20.

Department of Radiology, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey.

Background: Umbilical vein catheterization (UVC) is an early venous access route in newborns and is frequently used for delivering total parenteral nutrition (TPN) and medications. Vascular, hepatic parenchymal, and infectious complications of UVC can be seen rarely.

Objective: We present preterm neonates' X-ray, US, and MRI findings with parenchymal TPN extravasation and portal vein thrombosis. Read More

View Article and Full-Text PDF

The efficacy of transarterial chemoembolization in downstaging unresectable hepatocellular carcinoma to curative therapy: a predicted regression model.

Invest New Drugs 2022 Jun 20. Epub 2022 Jun 20.

Department of General Surgery (Hepatobiliary Surgery), The Affiliated Hospital of Southwest Medical University, Sichuan Province, Luzhou City, China.

Patients with hepatocellular carcinoma (HCC) outside Milan criteria (MC) may be candidates for curative therapy after successful downstaging. We aimed to identify the predictors of successful downstaging of unresectable HCC in patient by transarterial chemoembolization (TACE) outside MC. We performed a retrospective study on patients with unresectable HCC outside MC who received downstaging with TACE. Read More

View Article and Full-Text PDF

Prospective validation to prevent symptomatic portal vein thrombosis after liver resection.

World J Hepatol 2022 May;14(5):1016-1024

Department of Digestive Surgery, Nihon University School of Medicine, Tokyo 1738610, Japan.

Background: Portal vein thrombosis (PVT) after liver resection is rare but can lead to life-threatening liver failure. This prospective study evaluated patients using contrast-enhanced computed tomography (E-CT) on the first day after liver resection for early PVT detection and management.

Aim: To evaluate patients by E-CT on the first day after liver resection for early PVT detection and immediate management. Read More

View Article and Full-Text PDF

A Dynamic Nomogram Predicting Portal Vein Thrombosis in Cirrhotic Patients During Primary Prophylaxis for Variceal Hemorrhage.

Front Med (Lausanne) 2022 3;9:887995. Epub 2022 Jun 3.

Department of Gastroenterology and Hepatology, School of Medicine, Shanghai Tongji Hospital, Tongji University, Shanghai, China.

Background: Portal vein thrombosis (PVT) would exert a further increase in resistance to portal blood flow, resulting in worsening portal hypertension and poor outcome. This study aimed to identify risk factors and develop an clinically applicable dynamic nomogram predicting the occurrence of PVT in cirrhotic patients during primary prophylaxis for variveal hemorrhage (VH).

Methods: The multi-center retrospective study enrolled cirrhotic patients with high-risk varices, which were further divided into training and validation cohorts for 3 years follow-up. Read More

View Article and Full-Text PDF

Risk Factors, Clinical Presentation, Diagnosis, and Treatment Outcomes of Portal Vein Thrombosis: A Five-Year Hospital-Based Study From Qatar.

J Clin Med Res 2022 May 31;14(5):209-217. Epub 2022 May 31.

Department of Medicine, Hamad General Hospital, Doha, Qatar.

Background: There is a lack of robust epidemiological information on portal vein thrombosis (PVT) in Qatar. This study aimed to describe the risk factors, clinical presentation, diagnosis, and treatment outcomes of PVT in patients with and without liver cirrhosis admitted to Hamad General Hospital.

Methods: This retrospective observational study was conducted at Hamad General Hospital, Doha, Qatar. Read More

View Article and Full-Text PDF

[Prevalence and etiological profiles of atypical localization venous thrombosis : A descriptive multicenter study].

Ann Cardiol Angeiol (Paris) 2022 Jun 16. Epub 2022 Jun 16.

Service de Médecine Interne, Centre hospitalier Universitaire Joseph Raseta Befelatanana, Antananarivo, Madagascar.

Introduction: Venous thrombosis of unusual sites is much rarer than in the lower limbs and requires a rigorous etiological approach. The objective was to describe the clinical and progressive peculiarities of unusual localization venous thrombosis as well as their etiologies.

Patients And Methods: Multicenter descriptive retrospective study of hospitalized patient records in the two large Hospital Centers, Antananarivo, Madagascar between 2017 and 2020 in which the diagnosis of unusual venous thrombosis was confirmed by imaging. Read More

View Article and Full-Text PDF

Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study.

J Immunother Cancer 2022 Jun;10(6)

Division of Hematology and Medical Oncology, Mount Sinai School of Medicine, New York City, New York, USA

Background: Immune checkpoint inhibitors (ICIs) have revolutionized treatment of advanced hepatocellular carcinoma. Integrated use of transarterial chemoembolization (TACE), a locoregional inducer of immunogenic cell death, with ICI has not been formally assessed for safety and efficacy outcomes.

Methods: From a retrospective multicenter dataset of 323 patients treated with ICI, we identified 31 patients who underwent >1 TACE 60 days before or concurrently, with nivolumab at a single center. Read More

View Article and Full-Text PDF

Spleen bed laparoscopic splenectomy plus pericardial devascularization for elderly patients with portal hypertension.

Wideochir Inne Tech Maloinwazyjne 2022 Jun 16;17(2):338-343. Epub 2022 Mar 16.

Department of Hepatobiliary Surgery, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou, China.

Introduction: Laparoscopy splenectomy has been a preferred choice over open surgery, but limited studies dealing with laparoscopy splenectomy plus pericardial devascularization (LSPD) for elderly patients are available.

Aim: To assess the safety and long-term efficacy of spleen bed LSPD for elderly patients with portal hypertension.

Material And Methods: A total of 132 elderly patients (age > 60 years) suffering from portal hypertension were operated on in the department. Read More

View Article and Full-Text PDF

Laparoscopic splenectomy and esophagogastric devascularization combined with fast-track principles offers greater benefit for patients with portal hypertension.

Wideochir Inne Tech Maloinwazyjne 2022 Jun 19;17(2):326-337. Epub 2022 Jan 19.

Department of General Surgery, TangDu Hospital, Fourth Military Medical University, Xi'an, Shannxi Province, China.

Introduction: Laparoscopic splenectomy and esophagogastric devascularization (LSED) is becoming increasingly popular in the treatment of esophageal-fundic variceal bleeding with portal hypertension (PHT) in China, and its high safety and minimal trauma have been proven. Fast-track (FT) surgery improves patient recovery and decreases postoperative complications.

Aim: To determine whether LSED with fast-track principles can provide better outcomes than traditional treatment for patients with PHT. Read More

View Article and Full-Text PDF

Research on Portal Venous Hemodynamics and Influencing Factors of Portal Vein System Thrombosis for Wilson's Disease after Splenectomy.

Front Surg 2022 30;9:834466. Epub 2022 May 30.

The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, China.

Objective: Splenectomy is one crucial solution for hypersplenism with portal hypertension. However, portal vein system thrombosis (PVST) caused by hemodynamic changes affects the prognosis of patients. We analyze the changes in portal vein hemodynamics following splenectomy for Wilson's disease combined with portal hypertension and the influencing factors that lead to PVST. Read More

View Article and Full-Text PDF

Portal Vein Thrombosis as a Cause of Undetermined Thrombocytopenia with Liver Dysfunction in a Patient with Eosinophilic Granulomatosis with Polyangiitis.

Intern Med 2022 Jun 14. Epub 2022 Jun 14.

Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Japan.

We herein report a 20-year-old woman who developed eosinophilic granulomatosis with polyangiitis (EGPA) and portal vein thrombosis (PVT). EGPA was diagnosed based on the patient's history of asthma, hypereosinophilia, and mononeuritis complex. Thrombocytopenia and liver dysfunction were observed, necessitating contrast-enhanced computed tomography (CECT), which revealed PVT. Read More

View Article and Full-Text PDF

Porto-sinusoidal vascular disorder.

J Hepatol 2022 Jun 8. Epub 2022 Jun 8.

Department for Visceral Medicine and Surgery, Inselspital, Bern University Hospital, University of Bern, Switzerland; Department of Biomedical Research, University of Bern, Bern, Switzerland.

It is well established that portal hypertension (PH) can occur in the absence of cirrhosis, as reported in patients with immune disorders, infections and thrombophilia. However, similar histological abnormalities affecting primarly the hepatic sinusoidal and the (peri)portal vasculature have also been observed in patients without PH. Thus, the term porto-sinusoidal vascular disorder (PSVD) has been recently introduced to describe a group of vascular diseases of the liver featuring lesions encompassing the portal venules and sinusoids, irrespective of the absence or presence of portal hypertension. Read More

View Article and Full-Text PDF

Epidemiology of portal vein thrombosis in liver cirrhosis: A systematic review and meta-analysis.

Eur J Intern Med 2022 Jun 7. Epub 2022 Jun 7.

Liver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang 110840, PR China; Postgraduate College, Shenyang Pharmaceutical University, Shenyang 110016, PR China; Postgraduate College, China Medical University, Shenyang 110122, PR China. Electronic address:

Background: Portal vein thrombosis (PVT) may be associated with negative outcomes in patients with liver cirrhosis. However, the prevalence and incidence of PVT in liver cirrhosis are heterogeneous among studies and have not been sufficiently determined yet.

Methods: The PubMed, EMBASE, and Cochrane Library databases were searched. Read More

View Article and Full-Text PDF

Outcome of living donor liver transplantation in patients with preoperative portal vein thrombosis.

Arab J Gastroenterol 2022 Jun 7. Epub 2022 Jun 7.

Department of Tropical Medicine, Ain Shams Center for Organ Transplantation (ASCOT), Ain Shams University, Cairo, Egypt.

Background And Study Aims: Portal vein thrombosis (PVT) is no longer an absolute contraindication for living donor liver transplantation (LDLT). This study aimed to assess the short-term outcomes of LDLT and compare the 1-year survival rates between patients with and without preoperative PVT.

Patients And Methods: This combined prospective and retrospective cohort study was conducted on patients who underwent LDLT at Ain Shams Centre for Organ Transplantation (ASCOT) between 2008 and 2020. Read More

View Article and Full-Text PDF

The Effect of Pre-transplant Lipid Profile on Post-transplant Hepatocellular Carcinoma Recurrence: Retrospective Single-Center Analysis.

Turk J Gastroenterol 2022 May;33(5):434-442

Department of Surgery, Liver Transplantation Institute, İnönü University, Malatya, Turkey.

Background: Plasma lipids have been shown to relate to tumor biology. We aimed to analyze the effect of pre-transplant plasma lipid profiles on post-transplant tumor recurrence in patients with hepatocellular carcinoma and to identify any possible relationship between the pre-transplant lipid profile with maximum tumor diameter, number of tumor nodules, tumor differentiation, portal vein invasion, or serum biomarker levels.

Methods: Patients with hepatocellular carcinoma who underwent liver transplants between 2006 and 2021 had data collected pro- spectively and were analyzed retrospectively. Read More

View Article and Full-Text PDF

Imaging-guided interventions modulating portal venous flow: Evidence and controversies.

JHEP Rep 2022 Jul 4;4(7):100484. Epub 2022 Apr 4.

Université Paris Cité; AP-HP, Hôpital Beaujon, Service de Radiologie, Clichy; Centre de Recherche sur l'inflammation Inserm, UMR 1149, Paris, France.

Portal hypertension is defined by an increase in the portosystemic venous gradient. In most cases, increased resistance to portal blood flow is the initial cause of elevated portal pressure. More than 90% of cases of portal hypertension are estimated to be due to advanced chronic liver disease or cirrhosis. Read More

View Article and Full-Text PDF

Portal Vein Thrombosis in Cirrhosis.

J Clin Exp Hepatol 2022 May-Jun;12(3):965-979. Epub 2021 Nov 22.

Department of Gastroenterology, Seth GS Medical College and KEM Hospital, Mumbai, India.

Patients with cirrhosis of the liver are at high risk of developing portal vein thrombosis (PVT), which has a complex, multifactorial cause. The condition may present with a myriad of symptoms and can occasionally cause severe complications. Contrast-enhanced computed tomography (CT) is the gold standard for the diagnosis of PVT. Read More

View Article and Full-Text PDF
November 2021

Correlation of Clinicopathological Profile, Prognostic Factors, and Survival Outcomes with Baseline Alfa-Fetoprotein Levels in Patients With Hepatocellular Carcinoma: A Biomarker that is Bruised but Not Broken.

J Clin Exp Hepatol 2022 May-Jun;12(3):841-852. Epub 2021 Nov 16.

Department of Pathology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India.

Background And Aims: The role of Alfa-fetoprotein (AFP) in the management of hepatocellular carcinoma (HCC) is still debated, with differences in recommendations between international guidelines. We analyzed the relationship of the clinicopathological profile, prognostic features, and survival outcomes with baseline serum AFP levels in patients with HCC.

Methods: Retrospective analysis of a prospectively accrued dataset of consecutive HCC patients was done. Read More

View Article and Full-Text PDF
November 2021

Iatrogenic pseudoaneurysm of the middle meningeal artery during embolization of bilateral chronic subdural hematomas.

Interv Neuroradiol 2022 Jun 7:15910199221107250. Epub 2022 Jun 7.

Department of Radiology, 21614University of Michigan, Ann Arbor, MI 48109, USA.

Middle meningeal artery embolization has become an important treatment option for chronic subdural hematomas. While the treatment is safe, we present a unique case of development of an iatrogenic middle meningeal artery pseudoaneurysm during endovascular embolization with use of a dual-lumen balloon catheter used for injection of a liquid embolic agent. A 62-year-old man on Coumadin for portal vein thrombosis presented to the hospital with headache and supratherapeutic INR. Read More

View Article and Full-Text PDF

Primary myelofibrosis with thrombophilia as first symptom combined with thalassemia and Gilbert syndrome: A case report.

World J Clin Cases 2022 May;10(13):4161-4170

Department of Hematology, Peking Union Medical College Hospital, Beijing 100730, China.

Background: A 46-year-old Han man first had sigmoid sinus and transverse sinus venous thrombosis at the age of 42. At the age of 44, he once again developed thrombosis. Genetic testing showed heterozygous SERPINC1 mutation, bone marrow biopsy showed fibrosis grade 1 (MF-1), and JAK2 V617F mutation was positive, accompanied by UGT1A1 mutation and β-thalassemia gene mutation. Read More

View Article and Full-Text PDF

Percutaneous CT-guided superior mesenteric vein access for portal vein recanalization-transjugular intrahepatic portosystemic shunt.

Radiol Case Rep 2022 Aug 28;17(8):2603-2606. Epub 2022 May 28.

Division of Vascular and Interventional Radiology, Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland Medical Center, 22 S. Greene Street, Suite: G2K10, Baltimore, MD 21201, USA.

Portal vein recanalization-transjugular intrahepatic portosystemic shunt (PVR-TIPS) is a valuable technique in the treatment cirrhosis and portal vein (PV) thrombosis. Only a few studies have reported cases of utilizing the transmesenteric approach in the procedure's initial portal access. Here, we report the successful utilization of a CT-guided percutaneous puncture of the superior mesenteric vein (SMV) for PVR-TIPS in a patient with splenic vein thrombosis. Read More

View Article and Full-Text PDF

Clinical predictors for thrombus progression in cirrhotic patients with untreated splanchnic vein thrombosis.

Thromb Res 2022 May 27;216:1-7. Epub 2022 May 27.

Division of Hematology and Oncology, Oregon Health & Science University, Portland, OR, United States of America; Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, United States of America.

Introduction: Splanchnic vein thrombosis (SVT) occurs in a heterogenous group of patients secondary to a variety of risk factors including liver disease. Minimal data regarding natural history and outcomes of SVT exists to inform management decisions. As such, there is equipoise regarding the utility of anticoagulation in cirrhotic patients with SVT. Read More

View Article and Full-Text PDF

[Chinese expert consensus for laparoscopic esophagogastric devascularization(2021)].


Zhonghua Wai Ke Za Zhi 2022 Jun;60(6):509-516

Laparoscopic esophagogastric devascularization has the advantages of less trauma, less bleeding and faster recovery.In order to promote this technology in a scientific and standardized manner and to guide clinical practice, the Chinese Society of Spleen and Portal Hypertension Surgery, Chinese Medical Association, discussed and composed the "Chinese expert consensus for laparoscopic esophagogastric devascularization(2021)".This consensus adheres to the standardization and minimally invasive principles of surgical treatment of portal hypertension, and elaborates the surgical indications and contraindications, preoperative evaluation, surgical technical points and precautions, postoperative management and common complications, especially the prevention and treatment of portal vein thrombosis. Read More

View Article and Full-Text PDF

The Efficacy and Safety of Anticoagulants in the Treatment of Cirrhotic Portal Vein Thrombosis: A Systematic Review and Meta-Analysis.

Clin Appl Thromb Hemost 2022 Jan-Dec;28:10760296221104797

Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, China.

Objective: To evaluate the efficacy and safety of anticoagulant therapy in patients with cirrhotic PVT, and compare differences in efficacy and safety among different anticoagulants.

Methods: We comprehensively searched Pubmed, Cochrane Library, EMBASE, and ClinicalTrials.gov from inception to April 2022 for studies using anticoagulants for cirrhotic PVT. Read More

View Article and Full-Text PDF

Efficacy and safety of chemoradiation therapy using one-shot cisplatin via hepatic arterial infusion for advanced hepatocellular carcinoma with major macrovascular invasion: a single-arm retrospective cohort study.

BMC Gastroenterol 2022 Jun 2;22(1):275. Epub 2022 Jun 2.

Department of Gastroenterology and Metabolism, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Background: Patients with hepatocellular carcinoma (HCC) and macrovascular invasion (MVI) who receive systemic chemotherapy have a poor prognosis. This study aimed to determine if one-shot cisplatin (CDDP) chemotherapy via hepatic arterial infusion (HAI) combined with radiation therapy (RT) prior to systemic chemotherapy could improve the outcomes of these patients.

Methods: This study consisted of 32 HCC patients with the following eligibility criteria: (i) portal vein invasion 3/4 and/or hepatic vein invasion 2/3; (ii) received one-shot CDDP via HAI; (iii) received RT for MVI, (iv) a Child-Pugh score ≤ 7; and (v) an Eastern Clinical Oncology Group Performance Status score of 0 or 1. Read More

View Article and Full-Text PDF

Low utilization of external beam radiation therapy for patients with unresectable hepatocellular carcinoma: An analysis of the United Network for Organ Sharing database.

Int J Radiat Oncol Biol Phys 2022 May 30. Epub 2022 May 30.

Department of Radiation Medicine, Oregon Health & Science University, Portland, OR, USA. Electronic address:

Purpose/objective(s): External beam radiation therapy (EBRT) is a safe and emerging bridging liver-directed therapy (LDT) to liver transplantation (LT) for patients with hepatocellular carcinoma (HCC). The prevalence and clinical characteristics of patients receiving EBRT as a LDT for LT have not been evaluated. Our aim was to describe the utilization of EBRT in HCC patients evaluated for LT in the United States. Read More

View Article and Full-Text PDF

Safety and Efficacy of Liver-Directed Radiotherapy in Combination With Lenvatinib for Hepatocelluar Carcinoma With Macroscopic Tumor Thrombosis.

Front Oncol 2022 11;12:888755. Epub 2022 May 11.

Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.

Background: This study aimed to compare the clinical outcomes of patients with hepatocellular carcinoma (HCC) and macroscopic tumor thrombosis who were treated with lenvatinib with or without combined liver-directed radiotherapy (LRT).

Methods: From the institutional registry, we enrolled 82 patients diagnosed with HCC involving macroscopic tumor thrombosis and treated with lenvatinib monotherapy (non-LRT group, n = 54, 65.9%) or lenvatinib in combination with LRT (LRT group, n = 28, 34. Read More

View Article and Full-Text PDF